Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese Male Subjects

This study has been completed.
Information provided by:
Wyeth is now a wholly owned subsidiary of Pfizer Identifier:
First received: July 24, 2007
Last updated: December 3, 2007
Last verified: December 2007

This study is being conducted to assess the safety and tolerability of ascending multiple oral doses of SCA-136 administered to healthy Japanese male subjects.

Condition Intervention Phase
Drug: SCA-136
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: An Ascending Multiple Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of SCA-136 Administered Orally to Healthy Japanese Male Subjects

Resource links provided by NLM:

Further study details as provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Primary Outcome Measures:
  • Adverse events, safety laboratory results, vital signs, and ECGs will be used to monitor subject safety.

Estimated Enrollment: 24
Study Start Date: July 2007
Study Completion Date: October 2007

Ages Eligible for Study:   20 Years to 45 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion criteria:

  • Healty Japanese men willing to use a medically acceptable form of contraception.

Exclusion criteria:

  • Any significant disease
  • Positive urine drug screen
  • Increased liver function tests
  • Use of prescription drugs.
  Contacts and Locations
Please refer to this study by its identifier: NCT00505973

Ikebukuro, Toshima-ku, Japan, 171-0014
Sponsors and Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
  More Information

No publications provided Identifier: NCT00505973     History of Changes
Other Study ID Numbers: 3153A1-1114
Study First Received: July 24, 2007
Last Updated: December 3, 2007
Health Authority: Japan: Pharmaceuticals and Medical Devices Agency

Additional relevant MeSH terms:
Schizophrenia and Disorders with Psychotic Features
Mental Disorders processed this record on April 17, 2014